Published in Cancer Res on June 01, 2007
Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene (2010) 2.10
MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene (2012) 2.03
MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells. Oncogene (2011) 1.86
Perineural invasion and associated pain in pancreatic cancer. Nat Rev Cancer (2011) 1.64
MUC1 oncoprotein suppresses activation of the ARF-MDM2-p53 pathway. Cancer Biol Ther (2008) 1.51
MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Proc Natl Acad Sci U S A (2012) 1.44
Functional targeting of the MUC1 oncogene in human cancers. Cancer Biol Ther (2009) 1.39
Phosphorylation of MUC1 by Met modulates interaction with p53 and MMP1 expression. J Biol Chem (2008) 1.31
Mucin-interacting proteins: from function to therapeutics. Trends Biochem Sci (2009) 1.31
MUC1 and metastatic cancer: expression, function and therapeutic targeting. Cell Adh Migr (2013) 1.31
Cross talk between hedgehog and epithelial-mesenchymal transition pathways in gastric pit cells and in diffuse-type gastric cancers. Br J Cancer (2008) 1.24
The reactive tumor microenvironment: MUC1 signaling directly reprograms transcription of CTGF. Oncogene (2010) 1.23
Neural invasion in pancreatic cancer: the past, present and future. Cancers (Basel) (2010) 1.10
Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells. Clin Cancer Res (2014) 1.05
MUC1 mucin: a peacemaker in the lung. Am J Respir Cell Mol Biol (2008) 1.02
EGFR-mediated carcinoma cell metastasis mediated by integrin αvβ5 depends on activation of c-Src and cleavage of MUC1. PLoS One (2012) 1.00
Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras. Clin Cancer Res (2011) 1.00
Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer. BMC Cancer (2011) 0.98
MUC1 regulates PDGFA expression during pancreatic cancer progression. Oncogene (2012) 0.95
MUC1: a novel metabolic master regulator. Biochim Biophys Acta (2014) 0.92
Lack of Muc1-regulated beta-catenin stability results in aberrant expansion of CD11b+Gr1+ myeloid-derived suppressor cells from the bone marrow. Cancer Res (2009) 0.91
MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism. Oncotarget (2015) 0.91
MUC1 regulates expression of multiple microRNAs involved in pancreatic tumor progression, including the miR-200c/141 cluster. PLoS One (2013) 0.90
PDGF upregulates Mcl-1 through activation of β-catenin and HIF-1α-dependent signaling in human prostate cancer cells. PLoS One (2012) 0.89
E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion. BMC Cancer (2011) 0.88
MUC1 is a substrate for gamma-secretase. J Cell Biochem (2009) 0.88
Impact of MUC1 mucin downregulation in the phenotypic characteristics of MKN45 gastric carcinoma cell line. PLoS One (2011) 0.86
Mucins differently expressed in various ampullary adenocarcinomas. Diagn Pathol (2011) 0.86
Structure and function of human DnaJ homologue subfamily a member 1 (DNAJA1) and its relationship to pancreatic cancer. Biochemistry (2014) 0.84
MUC1 protein induces urokinase-type plasminogen activator (uPA) by forming a complex with NF-κB p65 transcription factor and binding to the uPA promoter, leading to enhanced invasiveness of cancer cells. J Biol Chem (2014) 0.84
MUC1c regulates cell survival in pancreatic cancer by preventing lysosomal permeabilization. PLoS One (2012) 0.82
MUC1 Predicts Colorectal Cancer Metastasis: A Systematic Review and Meta-Analysis of Case Controlled Studies. PLoS One (2015) 0.82
Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth. Oncotarget (2015) 0.79
Reduction in circulating pro-angiogenic and pro-inflammatory factors is related to improved outcomes in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega-3 fish oil. HPB (Oxford) (2012) 0.79
MUC1-C Oncoprotein Integrates a Program of EMT, Epigenetic Reprogramming and Immune Evasion in Human Carcinomas. Biochim Biophys Acta (2017) 0.78
Impact of p53 and PDGFR-β Expression on Metastasis and Prognosis of Patients with Pancreatic Cancer. World J Surg (2016) 0.77
MUC1-mediated metabolic alterations regulate response to radiotherapy in pancreatic cancer. Clin Cancer Res (2017) 0.76
Continuous Low-dose-rate Irradiation of Iodine-125 Seeds Inhibiting Perineural Invasion in Pancreatic Cancer. Chin Med J (Engl) (2016) 0.76
MUC1 drives c-Met-dependent migration and scattering. Mol Cancer Res (2012) 0.76
MUC1 stimulates EGFR expression and function in endometrial cancer. Oncotarget (2016) 0.75
MUC1 facilitates metabolomic reprogramming in triple-negative breast cancer. PLoS One (2017) 0.75
Functional Consequences of Differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream Effects on Signaling). Biomolecules (2016) 0.75
Helicobacter pylori and Gastric Inflammation: Role of MUC1 Mucin. J Pediatr Biochem (2012) 0.75
Genomic alterations in mucins across cancers. Oncotarget (2017) 0.75
Glucose limitation alters glutamine metabolism in MUC1 overexpressing pancreatic cancer cells. J Proteome Res (2017) 0.75
Mammalian ECD protein is a novel negative regulator of the PERK arm of unfolded protein response. Mol Cell Biol (2017) 0.75
Transmembrane Mucins: Signaling Receptors at the Intersection of Inflammation and Cancer. J Innate Immun (2017) 0.75
Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer (2004) 8.06
Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med (2006) 4.46
Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res (2008) 3.59
Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol (2008) 3.34
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res (2003) 3.23
MUC1 cell surface mucin is a critical element of the mucosal barrier to infection. J Clin Invest (2007) 2.90
Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell (2005) 2.73
Cell surface-associated mucins in signal transduction. Trends Cell Biol (2006) 2.58
PDGF signaling in cells and mice. Cytokine Growth Factor Rev (2004) 2.57
Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol (2002) 2.22
A type III effector ADP-ribosylates RNA-binding proteins and quells plant immunity. Nature (2007) 2.19
MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am J Clin Pathol (2002) 2.18
Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteins. J Cell Biochem (2007) 1.87
MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene (2004) 1.86
Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res (2002) 1.81
Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res (2010) 1.79
Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst (2013) 1.78
MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. Cancer Res (2008) 1.77
The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays. Mol Cell Proteomics (2009) 1.77
Regulation of mucin genes in chronic inflammatory airway diseases. Am J Respir Cell Mol Biol (2006) 1.74
Nuclear association of the cytoplasmic tail of MUC1 and beta-catenin. J Biol Chem (2003) 1.73
Reaction mechanism, evolutionary analysis, and role of zinc in Drosophila methionine-R-sulfoxide reductase. J Biol Chem (2002) 1.68
Total pancreatectomy and islet autotransplantation in chronic pancreatitis: recommendations from PancreasFest. Pancreatology (2013) 1.67
Attenuated expression of profilin-1 confers protection from atherosclerosis in the LDL receptor null mouse. Circ Res (2007) 1.64
Collagen I promotes metastasis in pancreatic cancer by activating c-Jun NH(2)-terminal kinase 1 and up-regulating N-cadherin expression. Cancer Res (2006) 1.61
Notch 2-positive progenitors with the intrinsic ability to give rise to pancreatic ductal cells. Lab Invest (2005) 1.59
Pathologic features of mucin-producing bile duct tumors: two histopathologic categories as counterparts of pancreatic intraductal papillary-mucinous neoplasms. Am J Surg Pathol (2004) 1.59
MUC1 mucin is a negative regulator of toll-like receptor signaling. Am J Respir Cell Mol Biol (2007) 1.57
Increased levels of mucins in the cystic fibrosis mouse small intestine, and modulator effects of the Muc1 mucin expression. Am J Physiol Gastrointest Liver Physiol (2006) 1.57
Phosphorylation of claudin-5 and occludin by rho kinase in brain endothelial cells. Am J Pathol (2008) 1.55
Cutting edge: enhanced pulmonary clearance of Pseudomonas aeruginosa by Muc1 knockout mice. J Immunol (2006) 1.54
MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion. Oncogene (2003) 1.54
A new link between the c-Abl tyrosine kinase and phosphoinositide signalling through PLC-gamma1. Nat Cell Biol (2003) 1.53
Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology (2005) 1.50
Platelet-derived growth factor receptor-mediated signal transduction from endosomes. J Biol Chem (2003) 1.49
Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Res (2003) 1.47
Advancing a clinically relevant perspective of the clonal nature of cancer. Proc Natl Acad Sci U S A (2011) 1.47
HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. Clin Cancer Res (2012) 1.47
Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc Natl Acad Sci U S A (2011) 1.46
A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Med (2010) 1.46
MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Proc Natl Acad Sci U S A (2012) 1.44
MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology (2004) 1.43
Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis. Cancer Res (2011) 1.43
A potential role for PDGF-C in experimental and clinical proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci (2007) 1.41
RNA interference suppression of MUC1 reduces the growth rate and metastatic phenotype of human pancreatic cancer cells. Clin Cancer Res (2006) 1.40
Axl is essential for VEGF-A-dependent activation of PI3K/Akt. EMBO J (2012) 1.38
Cathepsin B regulates the intrinsic angiogenic threshold of endothelial cells. Mol Biol Cell (2005) 1.35
Phosphorylation of MUC1 by Met modulates interaction with p53 and MMP1 expression. J Biol Chem (2008) 1.31
Growth factors outside of the platelet-derived growth factor (PDGF) family employ reactive oxygen species/Src family kinases to activate PDGF receptor alpha and thereby promote proliferation and survival of cells. J Biol Chem (2009) 1.31
SelT, SelW, SelH, and Rdx12: genomics and molecular insights into the functions of selenoproteins of a novel thioredoxin-like family. Biochemistry (2007) 1.31
A NHERF binding site links the betaPDGFR to the cytoskeleton and regulates cell spreading and migration. J Cell Sci (2004) 1.30
Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer. Clin Cancer Res (2013) 1.28
Pathobiological implications of MUC16 expression in pancreatic cancer. PLoS One (2011) 1.26
In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Clin Cancer Res (2005) 1.23
Mdm2 binds to Nbs1 at sites of DNA damage and regulates double strand break repair. J Biol Chem (2005) 1.22
Intestinal mucins from cystic fibrosis mice show increased fucosylation due to an induced Fucalpha1-2 glycosyltransferase. Biochem J (2002) 1.22
A micropapillary pattern is predictive of a poor prognosis in lung adenocarcinoma, and reduced surfactant apoprotein A expression in the micropapillary pattern is an excellent indicator of a poor prognosis. Mod Pathol (2007) 1.22
Pericytes and ocular diseases. Exp Eye Res (2007) 1.21
Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol (2004) 1.21
The lectin domains of polypeptide GalNAc-transferases exhibit carbohydrate-binding specificity for GalNAc: lectin binding to GalNAc-glycopeptide substrates is required for high density GalNAc-O-glycosylation. Glycobiology (2007) 1.21
Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res (2005) 1.21
Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy. Exp Eye Res (2009) 1.19
Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation. J Neurochem (2006) 1.19
Protein kinase A-dependent translocation of Hsp90 alpha impairs endothelial nitric-oxide synthase activity in high glucose and diabetes. J Biol Chem (2007) 1.18
Characterization of glycation adducts on human serum albumin by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chim Acta (2007) 1.18
Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res (2004) 1.18
The gastric mucus layers: constituents and regulation of accumulation. Am J Physiol Gastrointest Liver Physiol (2008) 1.17
ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas. J Biol Chem (2002) 1.17
Loss of fibulin-2 expression is associated with breast cancer progression. Am J Pathol (2007) 1.17
Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer. J Immunother (2003) 1.16
SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans. J Clin Invest (2011) 1.16
Comparison of modification sites formed on human serum albumin at various stages of glycation. Clin Chim Acta (2010) 1.14
Bidirectional signaling links the Abelson kinases to the platelet-derived growth factor receptor. Mol Cell Biol (2004) 1.14
MUC1 alters oncogenic events and transcription in human breast cancer cells. Breast Cancer Res (2006) 1.13
Involvement of phospholipase D2 in lysophosphatidate-induced transactivation of platelet-derived growth factor receptor-beta in human bronchial epithelial cells. J Biol Chem (2003) 1.12
Origin of the polycomb repressive complex 2 and gene silencing by an E(z) homolog in the unicellular alga Chlamydomonas. Epigenetics (2010) 1.12
N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy. Am J Pathol (2010) 1.11
Patterns of MUC1 tissue expression defined by an anti-MUC1 cytoplasmic tail monoclonal antibody in breast cancer. J Histochem Cytochem (2003) 1.10
Plasmin is the major protease responsible for processing PDGF-C in the vitreous of patients with proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci (2008) 1.10
PDGF receptor-α does not promote HCMV entry into epithelial and endothelial cells but increased quantities stimulate entry by an abnormal pathway. PLoS Pathog (2012) 1.10
Early detection of sporadic pancreatic cancer: summative review. Pancreas (2015) 1.10
Improved arene fluorination methodology for I(III) salts. Org Lett (2010) 1.09
Heat shock protein 90alpha-dependent translocation of annexin II to the surface of endothelial cells modulates plasmin activity in the diabetic rat aorta. Circ Res (2004) 1.09
MUC1 is a counter-receptor for myelin-associated glycoprotein (Siglec-4a) and their interaction contributes to adhesion in pancreatic cancer perineural invasion. Cancer Res (2007) 1.09
Tyrosines in the MUC1 cytoplasmic tail modulate transcription via the extracellular signal-regulated kinase 1/2 and nuclear factor-kappaB pathways. Mol Cancer Res (2006) 1.09
ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression. Int J Cancer (2008) 1.08
Peroxisome proliferator-activated receptor gamma controls Muc1 transcription in trophoblasts. Mol Cell Biol (2004) 1.08
Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology (2003) 1.07
Paramecium bursaria chlorella virus 1 proteome reveals novel architectural and regulatory features of a giant virus. J Virol (2012) 1.07
An in vivo gene therapy approach for experimental proliferative vitreoretinopathy using the truncated platelet-derived growth factor alpha receptor. Invest Ophthalmol Vis Sci (2002) 1.06